- Pharmacology
- Allergy, Immunology, and ENT
- Cardiology
- Emergency Medicine
- Endocrinology
- Adolescent Medicine
- Gastroenterology
- Infectious Diseases
- Neurology
- OB/GYN
- Practice Improvement
- Gynecology
- Respiratory
- Dermatology
- Mental, Behavioral and Development Health
- Oncology
- Rheumatology
- Sexual Health
- Pain
FDA advisory panel discusses COVID-19 vaccine expansion for Pfizer/BioNTech
The US Food and Drug Administration (FDA) is meeting to discuss amending the emergency use authorization of the Pfizer/BioNTech vaccine for children aged 5 to 11 years.
The US Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee is holding an all day meeting on October 26, 2021, to discuss the request from Pfizer/BioNTech to amend the Emergency Use Authorization to include children aged 5 to 11 years.
At the meeting, the Centers for Disease Control and Prevention will present on the epidemiology of COVID-19 in children and known safety signals which includes myocarditis in adolescents and young adults. Following a presentation from Pfizer-BioNTech for the expanded authorization, a review of the submission will occur as well an analysis of benefit versus risk. A 1 hour open public hearing session will occur at 1 PM.
The proceedings can be viewed live here.
